Protein-structure studies at the Advanced Light Source (ALS) helped demonstrate that the primary target of antibody-based COVID-19 immunity is the part of the virus’s spike protein that can most easily mutate. The work guides the selection of antibody therapeutics. https://als.lbl.gov/guiding-target-selection-for-covid-19-antibody-therapies/
January 2019 – July 2022
